{
    "clinical_study": {
        "@rank": "109272", 
        "acronym": "flixovate HAS", 
        "brief_summary": {
            "textblock": "this study has been request by french health authorities to evaluate the use of flixovate in\n      infants and its place in the treatment pathway.\n\n      this study has 2 main pbjectives: 1/ Evaluation of changes in the prescription share of\n      Flixovate\u00ae compared to other topical corticosteroids (low, medium and high potency) in the\n      population of infants aged from 3 to 12 months, from 1st January 2010 to 31st December 2012.\n      2/Description of the conditions of use of Flixovate\u00ae in infants aged less than 12 months\n      (infant profile, dosage form, dosage, treatment duration, prior, concomitant and subsequent\n      treatments etc.)."
        }, 
        "brief_title": "Place of Flixovate\u00ae in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Between 2010 and 2012 by French GPs and Private Paediatricians", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Dermatitis, Atopic", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Analysis of changes in share of prescriptions:\n\n          -  Infants who received at least one prescription of topical steroids between 1st\n             January 2010 and 31st December 2012.\n\n          -  Infants aged 3 to 12 months on the day of prescription of topical steroids.\n\n        Description of the conditions of use and patient profiles:\n\n          -  Infants who received at least one prescription of topical steroids between 1st\n             January 2010 and 31st December 2012.\n\n          -  Infants aged 3 to 12 months on the day of prescription of topical steroids.\n\n        Exclusion Criteria:\n\n          -  none"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Months", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "retrospective database extraction"
            }
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01920464", 
            "org_study_id": "116296"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 29, 2013", 
        "number_of_groups": "1", 
        "official_title": "Place of Flixovate\u00ae in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Between 2010 and 2012 by French GPs and Private Paediatricians", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "France: GSK observational study", 
                "France: CCTRIS, CNOM & CNIL", 
                "France: Haute Autorit\u00e9 de sant\u00e9 (HAS)"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "data collected and analysed: Profile of prescribers (age, sex, geographic location), Profile of infants (age, age group, gender, Z-score, medical history), Conditions (diagnoses corresponding to prescriptions of Flixovate\u00ae, dosage, mean duration of treatment and duration in classes, previous treatment, concomitant medications, treatments prescribed after discontinuation of Flixovate\u00ae. (emollients and other topical steroids).", 
                "measure": "Description of the conditions of use of Flixovate\u00ae in infants aged less than 12 months", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "data collected and analysed: Profile of prescribers (age, gender, geographical location). Number of prescriptions of Flixovate\u00ae and other topical steroids by class, INN and brand name", 
                "measure": "- Evaluation of changes in the prescription share of Flixovate\u00ae compared to other topical corticosteroids (low, medium and high potency) in the population of infants aged from 3 to 12 months, from 1st January 2010 to 31st December 2012.", 
                "safety_issue": "No", 
                "time_frame": "baseline, one year, 2 years, 3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01920464"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}